Jun 17, 2020
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
Jun 15, 2020
Global Prostate Cancer Market Analysis to 2028 - Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
May 13, 2020
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 03, 2020
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jun 27, 2018
Kangpu Biopharmaceuticals Launched Phase I Study of Novel Cancer Therapy Candidate KPG-121 in Patients with Metastatic Castration-Resistant Prostate Cancer in Collaboration with Accelovance, Inc.
Jun 27, 2018
NucleoBio Concludes Preliminary Tests For New Drug to Treat Aggressive Prostate Cancer
May 18, 2018
ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
May 17, 2018
AUA Releases Updates to Clinical Guideline on Castration-Resistant Prostate Cancer
Feb 16, 2018
Global Prostate Cancer Disease Coverage Forecast and Market Analysis 2018-2024: ADT Remains the Most Popular Treatment Choice
Feb 14, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
Feb 08, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018
UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer
Jan 25, 2018
Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA® (abiraterone acetate) and Erdafitinib
Dec 21, 2017
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Oct 11, 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer